The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Safety and efficacy of zanubrutinib in patients who are intolerant to ibrutinib and/or acalabrutinib
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the possibility of using zanubrutinib in patients who are intolerant to ibrutinib and/or acalabrutinib. Dr Shadman explains that zanubrutinib led to a lower rate of adverse events, including in patients who remained on zanubrutinib for a longer period of time than with ibrutinib and acalabrutinib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Epi Lilly: Consultancy; Adaptimmune: Consultancy; AstraZeneca: Consultancy, Research Funding; Epizyme: Consultancy; Mustang Bio: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Regeneron: Consultancy; Merck: Consultancy; Adaptive Biotechnologies: Consultancy; Morphosys/Incyte: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Sound Biologics: Consultancy; Kite Pharma: Consultancy; Abbvie: Consultancy, Research Funding; Atara Biotherapeutic: Consultancy, Research Funding; Celgene, a BMS Company: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding.
